Some Heterocyclic Hydrazone Compounds: Synthesis, Spectral Characterization and Anticancer Activity Study

Eyüp Başaran; Reşit Çakmak; Ercan Çınar; Ozge Cevik

doi:10.17776/csj.1099217

EN

Some Heterocyclic Hydrazone Compounds: Synthesis, Spectral Characterization and Anticancer Activity Study

Abstract

Cancer is currently ongoing to be a significant health problem threatening human health. Hydrazone compounds constitute a popular class of organic compounds used in novel drug discovery studies in therapy of cancer. In the current study, the preparation and structural characterization of some heterocyclic hydrazone compounds (7-12) and their anticancer capacities against HeLa cervical cancer and MCF-7 breast cancer cell lines were reported. The target compounds were characterized by some spectroscopic techniques (1H NMR, 13C NMR and FT-IR). The in vitro cytotoxic potentials of the target molecules were assessed by using MTT assay against two cancer cell lines. L929 mouse fibroblast cell lines were employed as normal cell. The results displayed that some of the tested molecules had varying anticancer activities. Among the tested compounds, compound 8 indicated anticancer activity against HeLa cells with IC50 value of 34.38 µM. On the other hand, of these tested compounds, compound 11 (IC50 = 26.84 µM) displayed anticancer activity against MCF-7 cells.

Keywords

Hydrazone derivatives, Anticancer activity, Breast cancer, Cervical cancer.

References

[1] De Silva D.D., Rapior S., Fons F., Bahkali A.H., Hyde, K.D., Medicinal mushrooms in supportive cancer therapies: an approach to anti-cancer effects and putative mechanisms of action, Fungal Divers., 55(1) (2012) 1-35.
[2] Atmaca H., Oğuz F., Ilhan S., Drug delivery systems for cancer treatment: a review of marine-derived polysaccharides, Curr. Pharm. Des., (2022).
[3] Küpeli Akkol E., Genç Y., Karpuz B., Sobarzo-Sánchez E., Capasso, R., Coumarins and coumarin-related compounds in pharmacotherapy of cancer, Cancers., 12(7) (2020) 1959.
[4] Kashyap D., Garg V.K., Sandberg E.N., Goel N., Bishayee, A., Oncogenic and tumor suppressive components of the cell cycle in breast cancer progression and prognosis, Pharmaceutics., 13(4) (2021) 569.
[5] Luna J.I., Grossenbacher S.K., Murphy W.J., Canter, R. J., Targeting cancer stem cells with natural killer cell immunotherapy, Expert Opin. Biol. Ther., 17(3) (2017) 313-324.
[6] Weiss, T., Weller M., Roth, P., Immunological effects of chemotherapy and radiotherapy against brain tumors, Expert Rev. Anticancer Ther., 16(10) (2016) 1087-1094.
[7] Scarpa E.S., Fabrizio G., Di Girolamo M., A role of intracellular mono‐ADP‐ribosylation in cancer biology, The FEBS J., 280(15) (2013) 3551-3562.
[8] Mansoori B., Mohammadi A., Davudian S., Shirjang S., Baradaran, B., The different mechanisms of cancer drug resistance: a brief review, Adv. Pharm. Bull., 7(3) (2017) 339-348.
[9] Longley D.B., Johnston P.G., Molecular mechanisms of drug resistance, J. Pathol., 205(2) (2005) 275-292.
[10] Goodman L.S., Wintrobe M.M., Dameshek W., Goodman M.J., Gilman A., McLennan M.T., Nitrogen mustard therapy: Use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders, JAMA, 132(3) (1946) 126-132.

[11] Barinaga M., From bench top to bedside, Sci., 278(5340) (1997) 1036-1039.
[12] Calabresi P., Welch A.D., Chemotherapy of neoplastic diseases, Annu. Rev. Med., 13(1) (1962) 147-202.
[13] Carter S.K., Slavik M., Chemotherapy of cancer, Annu. Rev. Pharmacol., 14(1) (1974) 157-179.
[14] Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA cancer J. Clin., 71(3) (2021) 209-249.
[15] Cancer, UK, How Chemotherapy Drugs Work. Available at: https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/how-chemotherapy-drugs-work.html, 2021 (accessed 28 Mar 2022).
[16] Al-Mulla A., A review: biological importance of heterocyclic compounds, Der Pharma Chem., 9(13) (2017) 141-147.
[17] Çakmak R., Başaran E., Kaya S., Erkan S., Synthesis, spectral characterization, chemical reactivity and anticancer behaviors of some novel hydrazone derivatives: Experimental and theoretical insights, J. Mol. Struct., 1253 (2022) 132224.
[18] Başaran E., Haşimi N., Çakmak R., Çınar E., Synthesis, structural characterization, and biological evaluation of some hydrazone compounds as potential antioxidant agents, Russ. J. Bioorganic Chem., 48(1) (2022) 143-152.
[19] Tabbiche A., Bouchama A., Chafai N., Zaidi F., Chiter C., Yahiaoui M., Abiza A., New bis hydrazone: synthesis, x-ray crystal structure, DFT computations, conformational study and in silico study of the ınhibition activity of SARS-CoV-2, J. Mol. Struct., 1261 (2022) 132865.
[20] Aydin S., Kaushik-Basu N., Arora P., Basu A., Nichols D.B., Talele T.T., Akkurt M., Çelik I., Büyükgungör O., Kucukguzel Ş.G., Microwave assisted synthesis of some novel flurbiprofen hydrazide-hydrazones as anti-hcv ns5b and anticancer agents, Marmara Pharm. J., 17(1) (2013) 26-34.
[21] Şenkardeş S., Türe A., Ekrek S., Durak A.T., Abbak M., Çevik Ö., Kaşkatepe B., Küçükgüzel İ., Küçükgüzel G., Novel 2,6-disubstituted pyridine hydrazones: synthesis, anticancer activity, docking studies and effects on caspase-3-mediated apoptosis, J. Mol. Struct., 1223(2021) 128962-128969.
[22] Şenkardeş S., Han M.İ., Kulabaş N., Abbak M., Çevik Ö., Küçükgüzel İ., Küçükgüzel G., Synthesis, molecular docking and evaluation of novel sulfonyl hydrazones as anticancer agents and COX-2 ınhibitors, Mol. Divers., 24(3) (2020) 673-689.
[23] Şenkardeş S., Kaushik-Basu N., Durmaz I., Manvar D., Basu A., Atalay R., Kucukguzel, S.G., Synthesis of novel diflunisal hydrazide-hydrazones as anti-hepatitis c virus agents and hepatocellular carcinoma ınhibitors, Eur. J. Med. Chem., 108(27) (2016) 301-308.
[24] Aktar B.S.K., Sıcak Y., Tok T.T., Oruc-Emre E.E., Yağlıoğlu A.Ş., Iyidoğan A K., Öztürk M., Demirtaş I., Designing heterocyclic chalcones, benzoyl/sulfonyl hydrazones: An insight into their biological activities and molecular docking study, J. Mol. Struct., 1211 (2020) 128059.
[25] Karaman N., Sıcak Y., Taşkın-Tok T., Öztürk M., Karaküçük-İyidoğan A., Dikmen M., Oruç-Emre E.E., New piperidine-hydrazone derivatives: Synthesis, biological evaluations and molecular docking studies as AChE and BChE inhibitors, Eur. J. Med. Chem., 124 (2016) 270-283.
[26] Çakmak R., Başaran E., Şentürk M., Synthesis, characterization, and biological evaluation of some novel Schiff bases as potential metabolic enzyme inhibitors, Arch. Pharm., 355(4) (2022) 2100430.
[27] Qin H.L., Zhang Z.W., Ravindar L., Rakesh K.P., Antibacterial activities with the structure-activity relationship of coumarin derivatives, Eur. J. Med. Chem., 207 (2020) 112832.
[28] Çınar E., Başaran E., Erdoğan Ö., Çakmak R., Boğa M., Çevik Ö., Heterocyclic Schiff base derivatives containing pyrazolone moiety: Synthesis, characterization, and in vitro biological studies, J. Chin. Chem. Soc., 68(12) (2021) 2355-2367.
[29] Çakmak R., Başaran E., Boğa M., Erdoğan Ö., Çınar E., Çevik Ö., Schiff base derivatives of 4-aminoantipyrine as promising molecules: synthesis, structural characterization and biological activities, Russ. J. Bioorganic Chem., 48(2) (2022).
[30] Paşa S., Erdogan Ö., Cevik Ö., Design, synthesis and investigation of procaine based new Pd complexes as DNA methyltransferase inhibitor on gastric cancer cells, Inorg. Chem. Commun., 132 (2021) 108846.
[31] Sıcak Y., Investigation of antioxidant, anticholinesterase inhibitory, tyrosinase inhibitory and urease inhibitory activities of some hydrazone derivatives, Turk. J. Life Sci., 2(2) (2017) 165-170.
[32] Bozkurt E., Sıcak Y., Oruç-Emre E.E., Iyidoğan A.K., Öztürk, M., Design and bioevaluation of novel hydrazide-hydrazones derived from 4-acetyl-N-substituted benzenesulfonamide, Russ. J. Bioorganic Chem., 46(5) (2020) 702-714.
[33] Sıcak Y., Oruç‐Emre E.E., Öztürk M., Taşkın‐Tok T., Karaküçük‐Iyidoğan A., Novel fluorine‐containing chiral hydrazide‐hydrazones: Design, synthesis, structural elucidation, antioxidant and anticholinesterase activity, and in silico studies, Chirality., 31(8) (2019) 603-615.
[34] Aktar B.S.K., Sıcak Y., Tatar G., Emre E.E., Synthesis of benzoyl hydrazones having 4-hydroxy-3, 5-dimethoxy phenyl ring, theirbiological activities, and molecular modeling studies on enzyme inhibition activities, Turk. J. Chem., 46(1) (2022) 236-252.

Details

Primary Language

English

Subjects

-

Journal Section

Research Article

Authors

Eyüp Başaran ^*
0000-0002-7840-5919
Türkiye

Reşit Çakmak
0000-0003-0401-7419
Türkiye

Ercan Çınar
0000-0003-0419-7798
Türkiye

Ozge Cevik
0000-0002-9325-3757
Türkiye

Publication Date

September 30, 2022

Submission Date

April 6, 2022

Acceptance Date

September 7, 2022

Published in Issue

Year 2022 Volume: 43 Number: 3

DOI

https://doi.org/10.17776/csj.1099217

IZ

https://izlik.org/JA55SB82FP

APA

Başaran, E., Çakmak, R., Çınar, E., & Cevik, O. (2022). Some Heterocyclic Hydrazone Compounds: Synthesis, Spectral Characterization and Anticancer Activity Study. Cumhuriyet Science Journal, 43(3), 437-442. https://doi.org/10.17776/csj.1099217

AMA

1.Başaran E, Çakmak R, Çınar E, Cevik O. Some Heterocyclic Hydrazone Compounds: Synthesis, Spectral Characterization and Anticancer Activity Study. CSJ. 2022;43(3):437-442. doi:10.17776/csj.1099217

Chicago

Başaran, Eyüp, Reşit Çakmak, Ercan Çınar, and Ozge Cevik. 2022. “Some Heterocyclic Hydrazone Compounds: Synthesis, Spectral Characterization and Anticancer Activity Study”. Cumhuriyet Science Journal 43 (3): 437-42. https://doi.org/10.17776/csj.1099217.

EndNote

Başaran E, Çakmak R, Çınar E, Cevik O (September 1, 2022) Some Heterocyclic Hydrazone Compounds: Synthesis, Spectral Characterization and Anticancer Activity Study. Cumhuriyet Science Journal 43 3 437–442.

IEEE

[1]E. Başaran, R. Çakmak, E. Çınar, and O. Cevik, “Some Heterocyclic Hydrazone Compounds: Synthesis, Spectral Characterization and Anticancer Activity Study”, CSJ, vol. 43, no. 3, pp. 437–442, Sept. 2022, doi: 10.17776/csj.1099217.

ISNAD

Başaran, Eyüp - Çakmak, Reşit - Çınar, Ercan - Cevik, Ozge. “Some Heterocyclic Hydrazone Compounds: Synthesis, Spectral Characterization and Anticancer Activity Study”. Cumhuriyet Science Journal 43/3 (September 1, 2022): 437-442. https://doi.org/10.17776/csj.1099217.

JAMA

1.Başaran E, Çakmak R, Çınar E, Cevik O. Some Heterocyclic Hydrazone Compounds: Synthesis, Spectral Characterization and Anticancer Activity Study. CSJ. 2022;43:437–442.

MLA

Başaran, Eyüp, et al. “Some Heterocyclic Hydrazone Compounds: Synthesis, Spectral Characterization and Anticancer Activity Study”. Cumhuriyet Science Journal, vol. 43, no. 3, Sept. 2022, pp. 437-42, doi:10.17776/csj.1099217.

Vancouver

1.Eyüp Başaran, Reşit Çakmak, Ercan Çınar, Ozge Cevik. Some Heterocyclic Hydrazone Compounds: Synthesis, Spectral Characterization and Anticancer Activity Study. CSJ. 2022 Sep. 1;43(3):437-42. doi:10.17776/csj.1099217